SLC5A2 and heart failure: A randomized trial investigating empagliflozin in non-diabetic heart failure patients demonstrated that SGLT2 inhibitors significantly enhanced quality of life by improving left ventricular volumes, mass, systolic function, and functional capacity compared to placebo.